Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC
June 5th 2023Nivolumab plus ipilimumab and chemotherapy continued to show durable benefit at 4 years compared with chemotherapy alone as first-line therapy in patients with advanced non–small cell lung cancer, particularly in the PD-L1–negative and squamous populations.
Trastuzumab Deruxtecan Elicits Responses in Difficult-To-Treat HER2+ Solid Tumors
Fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity across a wide range of HER2 expressing solid tumors, including hard-to-treat tumors, according to findings from the phase 2 DESTINY-PanTumor02 trial.
Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer
The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.
Tovorafenib Presents Opportunity for Tumor Reduction in Pediatric Low-Grade Glioma
June 4th 2023Treatment with tovorafenib elicited encouraging and fast onset responses in heavily pretreated pediatric patients with low-grade glioma regardless of response assessment criteria, according to data from the phase 2 FIREFLY-1 trial that were presented at the 2023 ASCO Annual Meeting.
Dr Raghav on Trastuzumab Deruxtecan in HER2+ mCRC
June 4th 2023Kanwal P. S. Raghav, MBBS, MD, discusses primary findings from the phase 2 DESTINY-CRC02 trial (NCT04744831) of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with metastatic colorectal cancer with HER2 amplification or overexpression.
Benefits of Neoadjuvant Nivolumab/Chemo Elucidated in NSCLC Exploratory Analysis
Neoadjuvant nivolumab plus chemotherapy improved clinical outcomes vs chemotherapy alone in patients with resectable non–small cell lung cancer who received definitive surgery with numerical but not statistical improvements seen even when definitive surgery was not achieved.
Nirogacestat Provides Rapid and Sustained Pain Reduction for Patients With Desmoid Tumors
June 4th 2023Treatment with the investigational gamma secretase inhibitor nirogacestat allowed patients with progressing desmoid tumors to experience a significant and clinically meaningful reduction in several aspects of disease-related pain when compared with placebo.
The PD-1 and TIGIT bispecific rilvegostomig demonstrated promising early signs of tolerability and efficacy in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer following progression on at least 1 prior checkpoint inhibitor. according to initial findings from the phase 1/2 ARTEMIDE-01 study.
Talazoparib/Enzalutamide Combo Significantly Improves rPFS in HRR Gene–Altered mCRPC
June 4th 2023The combination of talazoparib and enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression-free survival when used as a first-line therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
BRCA Mutations Associated with Worse Survival in HRR-deficient mCRPC
June 4th 2023Patients with homologous recombination repair–deficient mutations and metastatic castration-resistant prostate cancer who also harbored BRCA mutations experienced poorer survival outcomes vs patients without BRCA mutations and those with non-BRCA HRR mutations, according to an analysis from the CAPTURE trial.
GC012F Remains Safe, Generates Durable Responses in Relapsed/Refractory Myeloma
The BCMA- and CD19-targeted CAR T-cell therapy GC012F continued to demonstrate a favorable safety profile with no new safety signals, and it elicited deep and durable responses in patients with relapsed/refractory multiple myeloma.
Vorasidenib Is Potential First Targeted Therapy for Low-Grade Glioma
Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.
Adjuvant Osimertinib Provides OS Benefit in EGFR+ Stage IB-IIIA NSCLC
Treatment with adjuvant osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with resected, EGFR-mutated, stage IB to IIIA non–small cell lung cancer.
Preoperative FOLFOX Is Noninferior to Preoperative Chemoradiation in Locally Advanced Rectal Cancer
Neoadjuvant treatment with fluorouracil, leucovorin, and oxaliplatin proved to be as effective as pelvic chemoradiation with fewer adverse effects in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery.
Mirvetuximab Soravtansine Positioned as New Standard in Frα+ Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine-gynx demonstrated a 35% reduction in the risk of disease progression or death compared with investigator’s choice of chemotherapy in patients with folate receptor alpha-high, platinum-resistant ovarian cancer.
Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy
Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.
BI 764532 Shows Early Efficacy, Manageable Tolerability in DLL3+ SCLC and Neuroendocrine Carcinoma
When administered at doses of 90 μg/kg or higher, the novel DLL3-targeting T-cell engager, BI 764532, was found to have an acceptable toxicity profile and to elicit encouraging responses in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.
Talquetamab Plus Daratumumab Produces Potent Responses in R/R Multiple Myeloma
June 4th 2023Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.
Dostarlimab Plus Chemo Leads to PFS Improvement in dMMR/MSI-H Advanced Endometrial Cancer
June 4th 2023The combination of dostarlimab with standard-of-care carboplatin and paclitaxel elicited a statistically significant and clinically meaningful improvement in progression-free survival vs carboplatin/paclitaxel plus placebo in patients with mismatch repair–deficient/microsatellite instability–high advanced or recurrent endometrial cancer.
Dr Roddie on Obe-cel in R/R B-ALL
June 3rd 2023Claire Roddie, MD, discusses the patient population and topline efficacy findings from the phase 1/2 FELIX trial, which is investigating the CD19-directed CAR T-cell therapy obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.